Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-051/00
A61M-036/14
출원번호
US-0434313
(1999-10-25)
발명자
/ 주소
Yang, David J.
Liu, Chun W.
Yu, Dong-Fang
Kim, E. Edmond
출원인 / 주소
Board of Regents, The University of Texas System
대리인 / 주소
Fulbright & Jaworski L.L.P.
인용정보
피인용 횟수 :
24인용 특허 :
13
초록▼
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used
The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.
대표청구항▼
1. A composition for imaging comprising: a) a radionuclide label; b) ethylenedicysteine; and c) a tissue specific ligand conjugated to said ethylenedicysteine, wherein the tissue specific ligand is an anticancer agent, a folate receptor targeting ligand, a tumor apoptotic cell targeting ligand,
1. A composition for imaging comprising: a) a radionuclide label; b) ethylenedicysteine; and c) a tissue specific ligand conjugated to said ethylenedicysteine, wherein the tissue specific ligand is an anticancer agent, a folate receptor targeting ligand, a tumor apoptotic cell targeting ligand, a tumor hypoxia cell targeting ligand or glutamate pentapeptide; and wherein said ethylenedicysteine forms an N2S2chelate with said radionuclide label. 2. The composition of claim 1, wherein said tissue specific ligand may be conjugated to said ethylenedicysteine on one or both acid arms of the ethylenedicysteine. 3. The composition of claim 1, wherein said radionuclide is 99mTc, 188Re, 186Re, 183Sm, 166Ho, 90Y, 89Sr, 67Ga, 68Ga, 111In, 183Gd, 59Fe, 225Ac, 212Bi, 211At, 64Cu or 62Cu. 4. The composition of claim 3, wherein said radionuclide is 99mTc. 5. The composition of claim 1, wherein said tissue specific ligand is an anticancer agent. 6. The composition of claim 5, wherein said anticancer agent may be selected from the group consisting of methotrexate, doxorubicin, tamoxifen, paclitaxel, topotecan, LHRH, mitomycin C, etoposide tomudex, podophyllotoxin, mitoxantrone, camptothecin, colchicine, endostatin, fludarabin, gemcitabine and tomudex. 7. The composition of claim 1, wherein the tissue specific ligand is a folate receptor targeting ligand. 8. The composition of claim 7, wherein the folate receptor targeting ligand is folate, methotrexate or tomudex. 9. The composition of claim 8, further defined as 99mTc-EC-folate. 10. The composition of claim 8, further defined as 99mTc-EC-methotrexate. 11. The composition of claim 8, further defined as 99mTc-EC-tomudex. 12. The composition of claim 1, wherein the tissue specific ligand is a tumor apoptotic cell targeting ligand or a tumor hypoxia targeting ligand. 13. The composition of claim 11, wherein the tissue specific ligand is annexin V, colchicine, nitroimidazole, mitomycin or metronidazole. 14. The composition of claim 12, further defined as 99mTc-EC-annexin V. 15. The composition of claim 12, further defined as 99mTc-EC-colchicine. 16. The composition of claim 12, further defined as 99mTc-EC-nitroimidazole. 17. The composition of claim 12, further defined as 99mTC-EC-metronidas. 18. The composition of claim 1, wherein the tissue specific ligand is glutamate pentapeptide. 19. The composition of claim 17, further defined as 99m Tc-EC-glutamate pentapeptide. 20. The composition of claim 1, further comprising a linker conjugating EC to said tissue specific ligand. 21. The composition of claim 19, wherein the linker is a water soluble peptide, glutamic acid, aspartic acid, bromo ethylacetate, ethylene diamine or lysine. 22. The composition of claim 20, wherein the tissue specific ligand is estradiol, topotecan, paclitaxel, raloxifen, etoposide, doxorubicin, mitomycin C, endostatin, annexin V, LHRH, octreotide, VIP, methotrexate or folic acid.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (13)
Low Philip Stewart (West Lafayette IN) Horn Mark Alan (Piscataway NJ) Heinstein Peter Frederick (West Lafayette IN), Composition and method for tumor imaging.
Bergstein Paul L. (Norwood MA) Cheesman Edward H. (Townsend MA) Watson Alan D. (Andover MA), Ester-substituted diaminedithiols and radiolabeled complexes thereof.
Marzilli Luigi G. ; Lipowska Malgorzata ; Hansen Lory ; Taylor ; Jr. Andrew, Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof.
Marzilli Luigi Gaetano ; Lipowska Malgorzata ; Hansen Lory ; Taylor ; Jr. Andrew, Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof.
Srinivasan Ananthachari (Kirkland WA) Fritzberg Alan R. (Edmonds WA) Jones David S. (Seattle WA), Metal radionuclide chelating compounds for improved chelation kinetics.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhanced transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Low Philip S. (West Lafayette IN) Horn Mark A. (West Lafayette IN) Heinstein Peter F. (West Lafayette IN), Method for enhancing transmembrane transport of exogenous molecules.
Butterfield Dennis E. ; Fujii Dennis K. ; Ladd David L. ; Snow Robert A. ; Tan Julia S. ; Toner John L., Segmented chelating polymers as imaging and therapeutic agents.
Reiley, Mark A.; Silber, B. Michael; Chen, Xiaoqi, COX-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers.
Kim, Jungahn; Kim, Kwang Ung; Hwang, Seung Sang; Hong, Soon Man; Kwak, Soonjong; Park, Joon Hyeong; Kim, Ji Hee; Shin, Dong Youn; Hwang, Soon Geun; Kim, Jang Seop; Ryu, Han Wook, Chain-end functionalized poly(ethykene oxide) and process for the preparation of a nano-sized transition metal or metal salt using the same.
Reiley, Mark A.; Silber, B. Michael; Medina, Julio; Kayser, Frank; Shrader, William D., Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging.
Yang, David; Yu, Dongfang; Chanda, Mithu; Azhdarinia, Ali; Oh, Changsok; Kim, E. Edmund, Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications.
Yang, David J.; Liu, Chun W.; Yu, Dong Fang; Kim, E. Edmund, Ethylenedicysteine (EC)-drug conjugates compositions and methods for tissue specific disease imaging.
Yang, David J.; Liu, Chun W.; Yu, Dong Fang; Kim, E. Edmund, Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging.
Yang, David J.; Oh, Chang-Sok; Kohanim, Saady; Yu, Dong-Fang; Mendez, Richard; Kim, E. Edmund, Image-guided therapy of myocardial disease: composition, manufacturing and applications.
Yang, David J.; Liu, Chun W.; Yu, Dong Fang; Kim, E. Edmund, Metal ion-labeled bis-aminoethanethiol-targeting ligand conjugates, compositions, and methods for tissue-specific disease imaging.
Hong, Young-Don; Choi, Sun Ju; Lee, So-Young; Lim, jae cheong; Lee, Dong Eun, N3S1 chelator-folate derivatives, preparation method thereof and composition for diagnosis or treatment of cancer containing the same as an active ingredient.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.